JP2023545497A5 - - Google Patents
Info
- Publication number
- JP2023545497A5 JP2023545497A5 JP2023522972A JP2023522972A JP2023545497A5 JP 2023545497 A5 JP2023545497 A5 JP 2023545497A5 JP 2023522972 A JP2023522972 A JP 2023522972A JP 2023522972 A JP2023522972 A JP 2023522972A JP 2023545497 A5 JP2023545497 A5 JP 2023545497A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- modified
- amino acid
- seq
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091891P | 2020-10-14 | 2020-10-14 | |
| US63/091,891 | 2020-10-14 | ||
| US202163248081P | 2021-09-24 | 2021-09-24 | |
| US63/248,081 | 2021-09-24 | ||
| PCT/US2021/055057 WO2022081890A1 (en) | 2020-10-14 | 2021-10-14 | Compositions and methods for treating glycogen storage disease type 1a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545497A JP2023545497A (ja) | 2023-10-30 |
| JP2023545497A5 true JP2023545497A5 (https=) | 2024-10-23 |
Family
ID=81208619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023522972A Pending JP2023545497A (ja) | 2020-10-14 | 2021-10-14 | グリコーゲン貯蔵症１ａ型を治療するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230383277A1 (https=) |
| EP (1) | EP4229195A4 (https=) |
| JP (1) | JP2023545497A (https=) |
| KR (1) | KR20230124553A (https=) |
| AU (1) | AU2021360919A1 (https=) |
| CA (1) | CA3198671A1 (https=) |
| WO (1) | WO2022081890A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| CA3128755C (en) | 2019-02-13 | 2024-06-04 | Beam Therapeutics Inc. | Compositions and methods for treating hemoglobinopathies |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2025194124A1 (en) * | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | Modified st1cas9 guide nucleic acids |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108281A1 (en) * | 2018-08-03 | 2020-02-06 | Beam Therapeutics Inc. | Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence |
| WO2020051562A2 (en) * | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| EP3847254A4 (en) * | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| US11946040B2 (en) * | 2019-02-04 | 2024-04-02 | The General Hospital Corporation | Adenine DNA base editor variants with reduced off-target RNA editing |
| WO2020168088A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| KR20210126680A (ko) * | 2019-02-13 | 2021-10-20 | 빔 테라퓨틱스, 인크. | 알파-1 항트립신 결핍증을 치료하기 위한 조성물 및 방법 |
| CN120174005A (zh) * | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| KR20240037299A (ko) * | 2021-07-23 | 2024-03-21 | 빔 테라퓨틱스, 인크. | Crispr/cas 편집 시스템용 가이드 rna |
-
2021
- 2021-10-14 CA CA3198671A patent/CA3198671A1/en active Pending
- 2021-10-14 WO PCT/US2021/055057 patent/WO2022081890A1/en not_active Ceased
- 2021-10-14 US US18/031,547 patent/US20230383277A1/en active Pending
- 2021-10-14 AU AU2021360919A patent/AU2021360919A1/en active Pending
- 2021-10-14 KR KR1020237016287A patent/KR20230124553A/ko active Pending
- 2021-10-14 EP EP21881115.6A patent/EP4229195A4/en active Pending
- 2021-10-14 JP JP2023522972A patent/JP2023545497A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023545497A5 (https=) | ||
| US20230026726A1 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
| AU2020223733B2 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| US20230018543A1 (en) | Crispr/cas-mediated gene conversion | |
| JP2022546608A5 (https=) | ||
| US20210380987A1 (en) | Crispr/cas-related methods and compositions for treating cystic fibrosis | |
| JP2026064992A (ja) | β異常ヘモグロビン症を治療するためのＣＲＩＳＰＲ／ＣＡＳ関連方法および組成物 | |
| JP2025170240A5 (https=) | ||
| US20170007679A1 (en) | Crispr/cas-related methods and compositions for treating hiv infection and aids | |
| CA3052275A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| JP2022545950A5 (https=) | ||
| JP2024534945A (ja) | 化学修飾を有するプライム編集のためのガイドｒｎａ | |
| WO2015148860A1 (en) | Crispr/cas-related methods and compositions for treating beta-thalassemia | |
| JP2022532139A5 (https=) | ||
| JP2024511621A5 (https=) | ||
| US20230340468A1 (en) | Methods for using guide rnas with chemical modifications | |
| JP2021522825A5 (https=) | ||
| JP2023507034A5 (https=) |